Silence Therapeutics (NASDAQ:SLN) Earns Outperform Rating from William Blair

Silence Therapeutics (NASDAQ:SLN)‘s stock had its “outperform” rating reissued by equities research analysts at William Blair in a report issued on Tuesday,RTT News reports.

A number of other research analysts also recently commented on the stock. Jefferies Financial Group assumed coverage on shares of Silence Therapeutics in a report on Tuesday, September 3rd. They issued a “buy” rating and a $40.00 price target for the company. Chardan Capital restated a “buy” rating and set a $55.00 target price on shares of Silence Therapeutics in a research report on Thursday, November 14th. Morgan Stanley restated an “overweight” rating and set a $49.00 price target on shares of Silence Therapeutics in a research report on Tuesday, October 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $75.00 target price on shares of Silence Therapeutics in a research note on Friday, November 15th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $57.20.

Silence Therapeutics Price Performance

NASDAQ SLN opened at $6.93 on Tuesday. The stock has a market capitalization of $207.40 million, a PE ratio of -4.41 and a beta of 1.30. Silence Therapeutics has a 1 year low of $5.81 and a 1 year high of $27.72. The business’s 50-day moving average is $17.35 and its 200 day moving average is $18.86.

Institutional Investors Weigh In On Silence Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC grew its holdings in shares of Silence Therapeutics by 10.5% in the first quarter. SG Americas Securities LLC now owns 7,000 shares of the company’s stock worth $151,000 after acquiring an additional 667 shares during the period. Redmile Group LLC purchased a new stake in shares of Silence Therapeutics in the first quarter valued at approximately $43,798,000. Janus Henderson Group PLC purchased a new stake in Silence Therapeutics during the first quarter worth $13,575,000. Lynx1 Capital Management LP lifted its holdings in shares of Silence Therapeutics by 123.4% during the 1st quarter. Lynx1 Capital Management LP now owns 526,642 shares of the company’s stock valued at $11,375,000 after purchasing an additional 290,855 shares during the last quarter. Finally, Legato Capital Management LLC acquired a new stake in Silence Therapeutics during the 2nd quarter worth about $376,000. Institutional investors own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.